Cargando…

Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers

Multidrug resistance (MDR) observed in tumors significantly hinders the efficacy of chemotherapy. Downregulation of efflux proteins, such as P-glycoprotein (P-gp), using small interfering RNA (siRNA) can be an effective way to minimize the resistance in tumors. In this study, monoclonal antibody 2C5...

Descripción completa

Detalles Bibliográficos
Autores principales: Yalamarty, Satya Siva Kishan, Filipczak, Nina, Li, Xiang, Pathrikar, Tanvi Vinod, Cotter, Colin, Torchilin, Vladimir P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324017/
https://www.ncbi.nlm.nih.gov/pubmed/35890364
http://dx.doi.org/10.3390/pharmaceutics14071470
_version_ 1784756703852494848
author Yalamarty, Satya Siva Kishan
Filipczak, Nina
Li, Xiang
Pathrikar, Tanvi Vinod
Cotter, Colin
Torchilin, Vladimir P.
author_facet Yalamarty, Satya Siva Kishan
Filipczak, Nina
Li, Xiang
Pathrikar, Tanvi Vinod
Cotter, Colin
Torchilin, Vladimir P.
author_sort Yalamarty, Satya Siva Kishan
collection PubMed
description Multidrug resistance (MDR) observed in tumors significantly hinders the efficacy of chemotherapy. Downregulation of efflux proteins, such as P-glycoprotein (P-gp), using small interfering RNA (siRNA) can be an effective way to minimize the resistance in tumors. In this study, monoclonal antibody 2C5 (mAb 2C5)-PEG(7k)-DOPE conjugates were post-inserted into the mixed dendrimer micelles containing generation 4 (G4) polyamidoamine (PAMAM)-PEG(2k)-DOPE and PEG(5k)-DOPE. The inherent amphiphilic nature of DOPE conjugates causes the copolymers to self-assemble to form a micelle, which can encapsulate hydrophobic chemotherapeutic drugs in its core. The siRNA electrostatically binds to the cationic charges on the G4 PAMAM dendrimer. The tumor-specific mAb 2C5 on the surface of these nano-preparations resulted in improved tumor targeting. This active targeting to tumors can cause increase in the drug and siRNA accumulation at the tumor site, and thereby minimizing the off-target effects. The micelles were shown to have higher cellular association and effectiveness in vitro. The immunomicelle preparation was also tested for cytotoxicity in breast (MDA-MB-231) and ovarian (SKOV-3TR) MDR cancer cell lines.
format Online
Article
Text
id pubmed-9324017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93240172022-07-27 Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers Yalamarty, Satya Siva Kishan Filipczak, Nina Li, Xiang Pathrikar, Tanvi Vinod Cotter, Colin Torchilin, Vladimir P. Pharmaceutics Article Multidrug resistance (MDR) observed in tumors significantly hinders the efficacy of chemotherapy. Downregulation of efflux proteins, such as P-glycoprotein (P-gp), using small interfering RNA (siRNA) can be an effective way to minimize the resistance in tumors. In this study, monoclonal antibody 2C5 (mAb 2C5)-PEG(7k)-DOPE conjugates were post-inserted into the mixed dendrimer micelles containing generation 4 (G4) polyamidoamine (PAMAM)-PEG(2k)-DOPE and PEG(5k)-DOPE. The inherent amphiphilic nature of DOPE conjugates causes the copolymers to self-assemble to form a micelle, which can encapsulate hydrophobic chemotherapeutic drugs in its core. The siRNA electrostatically binds to the cationic charges on the G4 PAMAM dendrimer. The tumor-specific mAb 2C5 on the surface of these nano-preparations resulted in improved tumor targeting. This active targeting to tumors can cause increase in the drug and siRNA accumulation at the tumor site, and thereby minimizing the off-target effects. The micelles were shown to have higher cellular association and effectiveness in vitro. The immunomicelle preparation was also tested for cytotoxicity in breast (MDA-MB-231) and ovarian (SKOV-3TR) MDR cancer cell lines. MDPI 2022-07-15 /pmc/articles/PMC9324017/ /pubmed/35890364 http://dx.doi.org/10.3390/pharmaceutics14071470 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yalamarty, Satya Siva Kishan
Filipczak, Nina
Li, Xiang
Pathrikar, Tanvi Vinod
Cotter, Colin
Torchilin, Vladimir P.
Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
title Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
title_full Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
title_fullStr Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
title_full_unstemmed Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
title_short Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
title_sort co-delivery of sirna and chemotherapeutic drug using 2c5 antibody-targeted dendrimer-based mixed micelles for multidrug resistant cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324017/
https://www.ncbi.nlm.nih.gov/pubmed/35890364
http://dx.doi.org/10.3390/pharmaceutics14071470
work_keys_str_mv AT yalamartysatyasivakishan codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers
AT filipczaknina codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers
AT lixiang codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers
AT pathrikartanvivinod codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers
AT cottercolin codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers
AT torchilinvladimirp codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers